Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Obsidian Therapeutics
Biotech
Bristol Myers inks extension to Obsidian cell therapy pact
Bristol Myers has inked a multi-year extension to its collaboration with Obsidian, securing itself the exclusive option to license cell therapies.
Nick Paul Taylor
Oct 27, 2022 10:25am
Obsidian bags $115M to untether cell therapy from toxic sidekick
Sep 9, 2021 8:00am
Vertex taps Obsidian in controllable genetic medicines deal
Apr 22, 2021 10:23am
Bristol Myers exercises option on Obsidian's CD40L cell therapy
Sep 15, 2020 9:25am
Gilman buckles in as Arrakis raises $75M—Chutes & Ladders
Apr 19, 2019 9:30am
Wotton named CEO of cell, gene therapy startup Obsidian
Apr 18, 2019 8:41am
